Neuroinflammation in Cognitive Decline Post-cardiac Surgery

Coronary Artery Disease Clinical Trial

— FOCUS  

Official title:

Neuroinflammation in Cognitive Decline Post-cardiac Surgery: The FOCUS Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04520802
• Other study ID #: NL.57785.091.16
• Secondary ID: 2016-002016-40CM
• Status: Completed
• Start date: February 18, 2019
• Est. completion date: July 1, 2022

Study information

• Verified date: March 2023
• Source: Radboud University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Major cardiovascular surgery is associated with postoperative cognitive decline (POCD), with a deterioration in memory, attention and speed of information processing. A multifactorial pathophysiology is presumed but this study focuses on the role of (neuro)inflammation in the development of POCD after coronary artery bypass grafting (CABG) surgery.

Description:

Systemic inflammation can activate the innate immune cells of the brain inducing neuroinflammation, which plays an important role in the pathogenesis of neurodegenerative disease. Major cardiovascular surgery induces a severe systemic inflammatory response.There is growing support that neuroinflammation is a pivotal factor in the development of postoperative cognitive decline (POCD) due to surgery-related systemic inflammation. Although the neuroinflammatory hypothesis is scientifically accepted, in vivo human data supporting the role of neuroinflammation in severe systemic inflammation such as major surgery are still lacking. In the last decades, several nuclear imaging tracers have been developed that can quantitatively measure microglial and astrocytic activation in vivo, by targeting the mitochondrial 18kDa translocator protein (TSPO). The investigators hypothesize that cardiac surgery induces a neuroinflammatory response and that its presence is related to acute and long term brain dysfunction postoperatively. This will be studied by pre- and postoperative PET brain imaging using a 18F-DPA-714 tracer targeting TSPO, combined with longitudinal neuropsychological examinations. Structural changes in the brain will be recorded on MRI prior to and after cardiac surgery to enable us to correct for the potentially confounding effects of neurovascular events on cognitive outcomes after CABG surgery.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 1, 2022
• Est. primary completion date: July 1, 2022
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Age > 50 years
• Planned for on-pump coronary artery bypass grafting surgery
• High-affinity binder or mixed-affinity binders based on rs6971 polymorphism for TSPO
• Chronic use of statins (defined as pre-hospital use)

Exclusion Criteria:

• Previous cardiac surgery.
• Pregnancy or wish to become pregnant within 2 weeks after PET-CT scan
• Contra-indication to undergo a PET/CT or MRI scan, including claustrophobia.
• Low-affinity binder based on rs6971 polymorphism for TSPO, or unable to determine rs6971 polymorphism.
• Patients with cognitive disorders that have not recovered enough to be able to understand the study leaflets and information for participation.
• Brain or spinal surgery within the last 6 months.
• Meningitis or brain infection within the last 6 months.
• Pre-existing dementia or neurodegenerative disease or cognitive impairment interfering with the ability to understand informational material about this research project.
• Presence of a CSF catheter or shunt.
• Patients with known brain tumors.
• Patients with brain injury (e.g. acute stroke, or subarachnoid hemorrhage) within the last 6 months.
• Severe brain trauma in previous medical history.
• Chronic (>2 weeks) use of immunosuppressive agents (see table 3.3.A).
• Concomitant diseases resulting in severe immunosuppression (e.g. HIV).
• Auto-immune or auto-inflammatory disease
• Active infection < 2 weeks prior to inclusion (defined as fever >38.5 or antibiotic treatment)
• Kidney failure, defined by a MDRD-GFR<15 ml/min/1.73m2
• Known contrast allergy for gadolinium
• Chronic use of neuroleptics, defined as pre-hospital use.
• Patients that do not speak Dutch or have disabilities that prevent accurate delirium diagnosis.
• Analphabetic patients.
• No written informed consent obtained.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Coronary Artery Disease
• Pathophysiology
• Postoperative Cognitive Complications
• Postoperative Cognitive Dysfunction

Intervention

Diagnostic Test:
• 18F-DPA-714 PET/CT neuroimaging
Pre- and postoperative neuroimaging using 18F-DPA-714 PET/CT and brain MRI. Longitudinal neuropsychological examinations (up to 6 months postoperatively) Blood samples are drawn to assess the severity of the systemic inflammatory response

Locations

Country	Name	City	State
Netherlands	Department of Intensive Care Medicine, Radboud university medical center	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Peters van Ton AM, Duindam HB, van Tuijl J, Li WW, Dieker HJ, Riksen NP, Meijer FA, Kessels RP, Kohn N, van der Hoeven JG, Pickkers P, Rijpkema M, Abdo WF. Neuroinflammation in cognitive decline post-cardiac surgery (the FOCUS study): an observational study protocol. BMJ Open. 2021 May 11;11(5):e044062. doi: 10.1136/bmjopen-2020-044062. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in TSPO PET tracer uptake at 3-7 days post-surgery	18F-DPA-714	3-7 days post-surgery minus preoperative (= day before surgery)
Secondary	Occurrence of postoperative cognitive dysfunction (POCD)	POCD diagnosis based on neuropsychological assessments including TMT A&B, Stroop I, II, III, WAIS-IV - digit span, LDST, RAVLT, RCFT, RBMT-3 face recognition, LFT and token test. POCD diagnosis is made when patients are newly impaired in one or more cognitive domains (memory, executive functioning, speed of processing and language), or when the average test rating has declined in more than one domain compared to baseline.	Baseline (preoperative), postoperative (3-7 days after surgery, 6 weeks and 6 months)
Secondary	Whole brain TSPO PET tracer uptake pre- and 3-7 days post-surgery	18F-DPA-714	pre- and 3-7 days post-surgery
Secondary	Pro- and anti-inflammatory in vivo cytokine concentrations [in pg/ml]	TNFa, IL6, IL-1B, IL10, IL-1RA	Day before surgery, during surgery (stop extracorporeal circulation (ECC)), after surgery (6 hours after stop ECC, 24 hours after incision, 3-7 days post-surgery and 6 weeks after surgery)
Secondary	Ex vivo cytokine production of stimulated monocytes [in ng/10^9 monocytes]	TNFa, IL6, IL1B, MCP1, IL10	Day before surgery, 3-7 days and 6 weeks after surgery
Secondary	Flowcytometry analysis to study the inflammatory phenotype of the cells	HLA-DR, CCR2, CD11b, CD14, CD16	Day before surgery, 3-7 days and 6 weeks after surgery
Secondary	Complete blood count	including leukocyte differentiation measured on an automated hematology analyzer	Day before surgery, during surgery (stop extracorporeal circulation (ECC)), after surgery (6 hours after stop ECC, 24 hours after incision, 3-7 days post-surgery and 6 weeks after surgery)
Secondary	Ex vivo cytokine production of healthy donor monocytes, after exposure to patient serum obtained during CABG surgery	Healthy donor monocytes will be exposed to patient serum obtained during surgery, to see whether this changes the ex vivo cytokine producing capacity (TNFa, IL6, IL10)	Perioperatively at stop extracorporeal circulation (ECC)
Secondary	Number of newly developed (ischemic and hemorrhagic) brain and vascular wall lesions		pre- and 3-7 days post-surgery
Secondary	Delta brain activity in three large scale brain networks involved in stress reactivity on resting-state fMRI		pre- and 3-7 days post-surgery

External Links

•   Pubmed link to publication of complete study protocol